肿瘤细胞治疗研究
ALL SOURCES
把在研试验和前沿论文合在一起看，按时间倒序排列。本页条数 = 前沿论文 + 临床试验两块之和（导航里的「临床试验」板块只收在招的那部分，不另计入）。
CD28-ICOS costimulation enhances the therapeutic efficacy of L1CAM-targeted CAR-T cells against ovarian and gastric cancers.
优化的 L1CAM 靶向 CAR-T 细胞在 OC 和 GC 的临床前模型中展现出强效、持久且抗原特异性的抗肿瘤活性，并具有良好的安全性特征。合理的 CAR 设计（CD28-ICOS 信号传导）与优化的递送策略相结合，为 L1CAM 靶向 CAR-T 疗法的临床开发提供了强有力的依据，尤其是在 L1CAM 阳性实体瘤患者中。
Chemical priming potentiates mesothelin-targeting chimeric antigen receptor-engineered NK-92 antitumor activity by improving tumor trafficking and cyt
这些发现表明，化学预处理可增强 CAR-NK 细胞功能，并提供了一种有前景的非基因策略来提升 CAR-NK 细胞对实体瘤模型的活性。
Surface Engineering of NK Cells with Poly-L-Glutamic Acid Enhances Tumor-Selective Immunotherapy Against Ovarian Cancer.
hiPSC-Derived M1 Macrophages Exhibit Synergistic Therapeutic Effects with Paclitaxel in Ovarian Cancer.
Systematic growth factor profiling platform for 3D tumor models reveals estradiol-responsive cellular mechanisms of immunotherapy resistance.
Enhanced anti-tumor efficacy of tumor-infiltrating lymphocytes by GITR agonist in ovarian cancer.
我们证明了在 TIL 培养早期加入激动性 GITR 抗体可提高 CD8+ T 细胞与 Treg 细胞的比例，并增强抗肿瘤 T 细胞免疫。用 GITR 激动剂增强 TIL 可能有利于改善基于 TIL 的 ACT 在 OC 中的临床结局。
Sphingosylphosphorylcholine Promotes Th9 Cell Differentiation Through Regulation of Smad3, STAT5, and β-Catenin Pathways.
Changes in the tumor immune microenvironment during disease progression in clear cell ovarian cancer.
我们描述了晚期卵巢透明细胞癌患者的肿瘤免疫微环境特征。复发后 PD-L1 和 CD8+T 细胞表达显著增加。是否可将此用于筛选适合在复发情况下接受免疫治疗的患者，值得进一步研究。
Trastuzumab-Mediated Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Enhances Natural Killer Cell Cytotoxicity in HER2-Overexpressing Ovarian Can
MEMBER ACCOUNT
登录成功会直接打开下一页。
